Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
暂无分享,去创建一个
[1] G. Russell. Pouchitis Following Ileal Pouch Anal Anastomosis , 2006 .
[2] D. Jewell,et al. Cancer surveillance in ulcerative colitis , 2005, The British journal of surgery.
[3] S. Hanauer,et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis , 1995, Digestive Diseases and Sciences.
[4] S. Hanauer,et al. Hazard rates for dysplasia and cancer in ulcerative colitis , 1989, Digestive Diseases and Sciences.
[5] G. Haber,et al. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using99mTc-labeled 5-ASA suppositories , 1987, Digestive Diseases and Sciences.
[6] M. Jay,et al. Retrograde spreading of hydrocortisone enema in inflammatory bowel disease , 1986, Digestive Diseases and Sciences.
[7] H. Janowitz,et al. Autoimmune hemolytic anemia in ulcerative colitis , 1979, Digestive Diseases and Sciences.
[8] M. V. M. Frcs,et al. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis , 2005, Digestive Diseases and Sciences.
[9] Alastair Forbes,et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.
[10] Noam Harpaz,et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. , 2003, Gastroenterology.
[11] J. Lewis,et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. , 2003, Gastroenterology.
[12] N. Harpaz,et al. The fate of indefinite dysplasia in ulcerative colitis , 2003 .
[13] W. Kremers,et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 2001, Gastroenterology.
[14] P. Brigidi,et al. Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.
[15] American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. , 2003, Gastroenterology.
[16] A. Cross,et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.
[17] D. Levine,et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis , 2002, American Journal of Gastroenterology.
[18] J. Achkar,et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. , 2002 .
[19] S. Targan,et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.
[20] S. Kakar,et al. The fate of low grade dysplasia in ulcerative colitis , 2002, American Journal of Gastroenterology.
[21] J. Bai,et al. Budesonide enema in pouchitis—a double‐blind, double‐dummy, controlled trial , 2002, Alimentary pharmacology & therapeutics.
[22] J. Mansfield,et al. A double‐blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis , 2002, Alimentary pharmacology & therapeutics.
[23] M. Stolte,et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses , 2001, Gut.
[24] J. Achkar,et al. A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute Pouchitis , 2001, Inflammatory bowel diseases.
[25] A. Weaver,et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease , 2001, Gut.
[26] D. Jewell,et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications , 2001, Diseases of the colon and rectum.
[27] A. Kornbluth,et al. Difficult differential diagnoses in IBD: ileitis and indeterminate colitis. , 2001, Seminars in gastrointestinal disease.
[28] T. Lipman,et al. AGA technical review on parenteral nutrition. , 2001, Gastroenterology.
[29] K. Petraki,et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. , 2001, Scandinavian journal of gastroenterology.
[30] J. Achkar,et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. , 2001, Gastroenterology.
[31] A. Zinsmeister,et al. A prospective cohort study of practice guidelines in inflammatory bowel disease , 2001, American Journal of Gastroenterology.
[32] L. Mortelmans,et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.
[33] W. Sandborn. Rational dosing of azathioprine and 6-mercaptopurine , 2001, Gut.
[34] K. Abrams,et al. The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.
[35] NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. , 2001, Southern medical journal.
[36] C. Bernstein. Neoplastic and other complications of inflammatory bowel disease , 2000, Current gastroenterology reports.
[37] L. Good,et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis , 2000, American Journal of Gastroenterology.
[38] B. Bonaz,et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.
[39] R. Thisted,et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis , 2000, American Journal of Gastroenterology.
[40] S. Targan,et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.
[41] A. Zinsmeister,et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival , 2000, Gut.
[42] D. Jewell,et al. Pharmacotherapy for inducing and maintaining remission in pouchitis. , 1998, The Cochrane database of systematic reviews.
[43] G. May,et al. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. , 2000, The Cochrane database of systematic reviews.
[44] N. Harpaz,et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. , 1999, Gastroenterology.
[45] C. Bernstein. Cancer surveillance in inflammatory bowel disease , 1999, Current gastroenterology reports.
[46] R. Odze,et al. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. , 1999, Gastroenterology.
[47] C. Bernstein. ALMs versus DALMs in ulcerative colitis: polypectomy or colectomy? , 1999, Gastroenterology.
[48] S. Wallach,et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.
[49] A. Sonnenberg,et al. The unsolved problem of surveillance for colorectal cancer in ulcerative colitis. , 1999, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[50] K. Shetty,et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis , 1999, American Journal of Gastroenterology.
[51] W. Sandborn. Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results , 1999, American Journal of Gastroenterology.
[52] J. Valentine,et al. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease , 1999, American Journal of Gastroenterology.
[53] Taylor,et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months , 1998, Alimentary pharmacology & therapeutics.
[54] S. Hanauer,et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. , 1998, Gastroenterology.
[55] Jacques P. Brown,et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .
[56] G. Porro,et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial , 1998, American Journal of Gastroenterology.
[57] A. Kornbluth,et al. Is cyclosporine as effective in chronic ul cerative colitis as in severe ulcerative colitis , 1998 .
[58] A. Zinsmeister,et al. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis , 1998, Cancer.
[59] S. Hanauer. How Do I Treat Erythema Nodosum, Aphthous Ulcerations, and Pyoderma Gangrenosum? , 1998, Inflammatory bowel diseases.
[60] S. Targan,et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. , 1997, The American journal of gastroenterology.
[61] Jacques P. Brown,et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.
[62] P. Rutgeerts,et al. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. , 1997, The American journal of gastroenterology.
[63] A. Amorosi,et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. , 1997, The American journal of gastroenterology.
[64] P. Skipworth,et al. Reliability of rectal biopsy in distinguishing between chronic inflammatory bowel disease and acute self‐limiting colitis , 1997, Histopathology.
[65] J. Marshall,et al. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. , 1997, Gut.
[66] K. Batts,et al. Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis , 1997, Annals of Internal Medicine.
[67] S Gallivan,et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. , 1997, Journal of clinical pathology.
[68] C. Bodian,et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. , 1996, The American journal of gastroenterology.
[69] Å. Danielsson,et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. , 1996, Gastroenterology.
[70] S. Targan,et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. , 1996, Gastroenterology.
[71] A. Lavy,et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. , 1996, Gastroenterology.
[72] M. Molinari,et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. , 1996, Archives of surgery.
[73] N. LaRusso,et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. , 1996, Gut.
[74] S. Hanauer,et al. An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis , 1996, Annals of Internal Medicine.
[75] L. Eriksson,et al. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential , 1995, Hepatology.
[76] J. Marshall,et al. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis , 1995, Alimentary pharmacology & therapeutics.
[77] R. Newcombe,et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. , 1995, The New England journal of medicine.
[78] D. Sachar. Maintenance therapy in ulcerative colitis and Crohn's disease. , 1995, Journal of clinical gastroenterology.
[79] A. Ekbom. Cancer Risk in Inflammatory Bowel Disease , 1995 .
[80] P. Lance,et al. Cancer surveillance in ulcerative colitis: more of the same or progress? , 1994, Gastroenterology.
[81] C. Williams,et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. , 1994, Gastroenterology.
[82] H. Adami,et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. , 1994, Gastroenterology.
[83] S. Hanauer,et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.
[84] M. Kamm,et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease , 1994, The Lancet.
[85] R G Newcombe,et al. Transdermal nicotine for active ulcerative colitis. , 1994, The New England journal of medicine.
[86] C. Bernstein,et al. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? , 1994, The Lancet.
[87] N. Harpaz,et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. , 1994, The American journal of gastroenterology.
[88] N. Harpaz,et al. Refractory pouchitis: does it reflect underlying Crohn's disease? , 1993, Gut.
[89] H. Sacks,et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. , 1993, Journal of clinical gastroenterology.
[90] J. H. Baron,et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day , 1992, Alimentary pharmacology & therapeutics.
[91] B. Korelitz,et al. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. , 1992, Gastroenterology.
[92] A. Axon,et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. , 1992, BMJ.
[93] D. Sachar,et al. Benign and malignant colorectal strictures in ulcerative colitis. , 1992, Gut.
[94] A. Zinsmeister,et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. , 1992, Mayo Clinic proceedings.
[95] C. Holdsworth,et al. Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine , 1992, Alimentary pharmacology & therapeutics.
[96] S. Lo,et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. , 1991, Annals of internal medicine.
[97] C. Bodian,et al. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. , 1991, Gut.
[98] W. Roediger. The starved colon—Diminished mucosal nutrition, diminished absorption, and colitis , 1990, Diseases of the colon and rectum.
[99] F. D'armiento,et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. , 1990, The American journal of gastroenterology.
[100] D. Sachar,et al. Management of severe hemorrhage in ulcerative colitis. , 1990, American journal of surgery.
[101] M. Milla,et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis , 1990, Diseases of the colon and rectum.
[102] A. Axon,et al. The role of azathioprine in the management of ulcerative colitis , 1990, Diseases of the colon and rectum.
[103] D. Jewell,et al. High‐Dose Methylprednisolone in the Treatment of Active Ulcerative Colitis , 1988, Journal of clinical gastroenterology.
[104] B. Korelitz,et al. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. , 1990, The American journal of gastroenterology.
[105] P. Gionchetti,et al. Pentasa in maintenance treatment of ulcerative colitis. , 1990, Gastroenterology.
[106] L. Sutherland. Topical treatment of ulcerative colitis. , 1990, The Medical clinics of North America.
[107] R. Haggitt. Differential diagnosis of colitis. , 1990, Monographs in pathology.
[108] J. Levine. Therapy of Inflammatory Bowel Disease. New Medical and Surgical Approaches , 1990, The Yale Journal of Biology and Medicine.
[109] S. Meltzer,et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.
[110] W. Kruis,et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. , 1989, Gut.
[111] J. Jass,et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. , 1989, Human pathology.
[112] R. Phillips,et al. Ileitis and pouchitis after colectomy for ulcerative colitis , 1989, The British journal of surgery.
[113] P. Rutgeerts,et al. Comparative efficacy of coated, oral 5‐aminosalicylic acid (Claversal * ) and sulphasalazine for maintaining remission of ulcerative colitis , 1989, Alimentary pharmacology & therapeutics.
[114] A. Zinsmeister,et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. , 1989, Gastroenterology.
[115] H. Janowitz,et al. The "natural history" of ulcerative colitis: an analysis of the placebo response. , 1989, Journal of clinical gastroenterology.
[116] P. Blok,et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. , 1988, Gastroenterology.
[117] D. Present,et al. Medical decompression of toxic megacolon by "rolling". A new technique of decompression with favorable long-term follow-up. , 1988, Journal of clinical gastroenterology.
[118] S. Riley,et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. , 1988, Gastroenterology.
[119] J. G. Walker,et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazine , 1988, Alimentary pharmacology & therapeutics.
[120] N. Greenberger,et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. , 1988, Gastroenterology.
[121] D. Jewell,et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. , 1988, Gut.
[122] C. H. Mason,et al. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. , 1988, Gut.
[123] Z. Fireman,et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. , 1988, Gastroenterology.
[124] D. Present,et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. , 1987, Gastroenterology.
[125] L. Sutherland,et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.
[126] P. Cann,et al. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. , 1987, Scandinavian journal of gastroenterology.
[127] H. Appelman,et al. Histopathology differentiates acute self-limited colitis from ulcerative colitis. , 1987, Gastroenterology.
[128] L. Sutherland,et al. 5-Aminosalicylic Acid Enemas in the Maintenance of Remission in Distal Ulcerative Colitis and Proctitis , 1987 .
[129] J. Heppell,et al. Toxic megacolon , 1986, Diseases of the colon and rectum.
[130] D. Jewell,et al. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. , 1986, Gut.
[131] J. Lennard-jones,et al. Controlled trial of bowel rest in the treatment of severe acute colitis. , 1986, Gut.
[132] W. Kraaz,et al. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. , 1986, Gastroenterology.
[133] D. Sachar,et al. A Comparison of Multiple Synchronous Colorectal Cancer in Ulcerative Colitis, Familial Polyposis Coli, and de Novo Cancer , 1986, Annals of surgery.
[134] A. Axon,et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. , 1985, Gut.
[135] G. Järnerot,et al. Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.
[136] C. Surawicz,et al. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. , 1984, Gastroenterology.
[137] A. Harries,et al. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. , 1983, British medical journal.
[138] M. Dew. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid , 1982, British medical journal.
[139] J. Lennard-jones,et al. Controlled trial of azathioprine in chronic ulcerative colitis. , 1982, British medical journal.
[140] B. Levin,et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. , 1981, Gastroenterology.
[141] A. Axon,et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. , 1980, Gastroenterology.
[142] R. Weinshilboum,et al. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.
[143] J. Waye. Endoscopy in inflammatory bowel disease. , 1980, Clinics in gastroenterology.
[144] M. Farthing,et al. Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis. , 1979, British medical journal.
[145] S. Geller,et al. Cancer in universal and left-sided ulcerative colitis: clinical and pathologic features. , 1979, The Mount Sinai journal of medicine, New York.
[146] S. Truelove,et al. FURTHER EXPERIENCE IN THE TREATMENT OF SEVERE ATTACKS OF ULCERATIVE COLITIS , 1978, The Lancet.
[147] J. Lennard-jones,et al. A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis. , 1977, Scandinavian journal of gastroenterology.
[148] H. Spiro,et al. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. , 1975, Gastroenterology.
[149] B. Levin,et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. , 1975, Gastroenterology.
[150] D. Jewell,et al. Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.
[151] S. Truelove,et al. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin) , 1973, Gut.
[152] F. Klion,et al. Fate of the rectum and distal colon after subtotal colectomy for ulcerative colitis. , 1969, Gut.
[153] S. Truelove,et al. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. , 1958, British medical journal.
[154] S. Truelove,et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.
[155] S. Truelove,et al. Cortisone in Ulcerative Colitis , 1954 .